Literature DB >> 15246012

Quantitative analysis of sinistrin in serum with high-performance liquid chromatography for renal function testing.

Karl Oettl1, Doris Payerl, Sabine Zitta, Thomas Müller, Willibald Estelberger, Gilbert Reibnegger.   

Abstract

Sinistrin, as inulin, is widely used as a marker for renal function testing. A reliable and accurate method with a simple sample preparation for the quantitative determination of sinistrin would be of advantage. We developed a high-performance liquid chromatography (HPLC)-based method with electrochemical detection for the quantitative measurement of sinistrin in serum and plasma. Sample preparation is easy and includes enzymatic removal of glucose, deproteinization, acid hydrolysis of sinistrin, and HPLC separation of fructose. The recovery of sinistrin from serum is the same as that from water and is near 100%. The method presented has a linear range up to 500 mg/L. The results from our method are in agreement with a fully enzymatic quantification (regression coefficient 1.01, coefficient of variation 0.97). Sinistrin concentrations in aqueous solutions can be measured down to 2mg/L with a coefficient of variation of 5.7%. Quantification in serum is primarily limited by its physiological fructose content. The sensitivity of the described method is sufficient for its use in renal function testing. We describe a method for quantification of sinistrin which allows accurate measurements especially at low concentrations and low sample volumes. This laboratory method may be used for obtaining sinistrin pharmacokinetics in renal function testing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246012     DOI: 10.1016/j.ab.2004.03.019

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  1 in total

1.  Renal function assessment in older adults.

Authors:  A Clara Drenth-van Maanen; Paul A F Jansen; Johannes H Proost; Toine C G Egberts; Arjan D van Zuilen; Dawi van der Stap; Rob J van Marum
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.